The defective acute leukemia viruses avian myeloblastosis virus (AMV) and E26 virus each contain an inserted cellular sequence related to the same highly conserved cellular gene, proto-amv. The oncogenes of these two retroviruses differ from this cellular proto-oncogene in gene structure, transcript structure, and gene product. AMV (7, 8) .
in the nucleus of cells transformed by these viruses. A protein of 110,000 Mr which is specifically inimunoprecipitated by antisera to amv peptides and may be the product of the normal cellular gene (proto-amv) has been located in the cytoplasm of cells that express proto-amv mRNA.
Avian myeloblastosis virus (AMV) is a retrovirus that acutely transforms avian myeloid cells in vivo and in vitro. Like other acute leukemia viruses, it contains transduced, highly conserved cellular sequences that have replaced viral sequences essential for replication (1, 2) . The protein-coding sequence of the oncogene (myb) of AMV appears to consist of three parts: a presumed short 5' sequence of 18 gag-derived base pairs (bp) spliced to 1113 bp from the 3' end of a transduced chicken DNA sequence (amv) of 1200 bp, and a contiguous 3'-terminal 33-bp env sequence (3) (4) (5) (6) (7) . The cellular insert (amv) represents an internal fragment of the normal proto-oncogene (proto-amv) from which it arose, including a common coding region and a cellular intronic sequence in which 5' viral-cellular recombination took place (6, 7) . proto-amv has not been completely mapped or sequenced, but it extends over at least 10 kilobases (kb) of chicken cellular DNA and contains at least six introns that are not present in AMV (7, 8) .
In leukemic myeloblasts, the AMV oncogene is expressed as a 2-kb spliced subgenomic mRNA (9, 10) . In contrast, proto-amv is expressed as a 4-kb transcript in normal and certain neoplastic hematopoietic tissues (11, 12) . This protoamv mRNA contains both 5' and 3' genetic information not present in AMV (ref. 13 ; unpublished data). In addition to differing gene and transcript structure, differing protein products of the AMV oncogene and proto-oncogene have also been found (3, 4) .
By using three antisera raised against different synthetic peptides predicted from the amv open reading frame, a common 48,000 Mr protein was specifically identified as the AMV oncogene product, p48mY', in AMV-transformed leukemic myeloblasts (3) . The same three antisera also specifically precipitated a 110,000 Mr candidate normal cellular homolog, p110Protoa'v, in hematopoietic tissues that express the 4-kb proto-amv message (3) .
As a first approach to analyzing the functions of the AMV oncogene product, we have determined its-intracellular location. In addition, we have determined the location of the putative transforming protein, p135sag8""I'ts, of the E26 leukemia virus, which contains an oncogene with both amv-related and -unrelated cellular sequences (ets) (14) (15) (16) (17) 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. cell lines (18) . Subcellular fractions obtained by differential centrifugation of Kyro-EOB-lysed leukemic myeloblasts reproducibly consisted of an intact nuclear pellet containing 90-95% of total [3H]thymidine-labeled DNA, a membranous postnuclear sediment, and a soluble postnuclear supernatant. The latter two fractions were essentially free of DNA.
After radioactive labeling, cells were washed with phosphate-buffered saline, pH 7.4, by centrifugation at 500 x g.
The cell pellets were gently resuspended with 300 A.l of phosphate-buffered saline and then diluted into 5 ml of ice-cold nuclear buffer (150 mM NaCl/150 mM sucrose/20 mM Hepes, pH 7.4/5 mM KCl/2 mM dithiothreitol/1 mM MgCl2/0.5 mM CaC12/0.1 mM phenylmethylsulfonyl fluoride/0.1 mM leupeptin/0.4 trypsin-inhibiting unit of aprotinin per ml) containing 0.1% Kyro-EOB (Proctor & Gamble). For bursal and thymic lymphocytes, 0.01% digitonin (Sigma) was substituted for Kyro-EOB (see below). This suspension was gently mixed with a pipet for 3 min on ice and then centrifuged at 500 x g for 10 min to pellet nuclei. The remaining postnuclear supernatant was then centrifuged at 100,000 x g for 60 min at 4°C. The pellets obtained from these two centrifugations were resuspended in 10 ml of detergent buffer (3) and designated the nuclear lysate (NUC) and membrane lysate (P100). The soluble supernatant (S100) was adjusted to 10 ml with concentrated detergent buffer. The NUC and P100 lysates were clarified by centrifugation at 100,000 X g for 60 min at 4°C prior to use in immunoprecipitation experiments.
Immunoprecipitation and Electrophoresis. Peptides, antipeptide antisera, immunoprecipitation, and electrophoresis in 7.5% polyacrylamide gels have been previously described (3) .
Specific Indirect Immunofluorescence. Rabbit antisera were preabsorbed with normal chicken liver tissue fragments prior to use. Single cell suspensions of cultured or freshly explanted cells were smeared onto microscope slides and air dried. Cells were permeabilized with acetone for 10 min and then washed with phosphate-buffered saline. The cells were then exposed to dilutions of rabbit preimmune serum, rabbit anti-peptide antiserum, or rabbit anti-peptide antiserum blocked with excess peptide. After 30 min at 25°C, the cells were washed again with phosphate-buffered saline. They were then exposed to fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Sigma) for 30 min at 25°C, washed with phosphate-buffered saline, and then mounted in phosphate-buffered saline/glycerol. Cells were examined by fluorescence microscopy and photographed with Kodak Ektachrome film (ASA 400) using 40-sec exposures.
RESULTS

Localization of the AMV Oncogene Product in Leukemic
Chicken Myeloblasts. Antisera raised against synthetic amvencoded peptides P1 and P4 (3) were used to determine the intracellular location of p48mYb in AMV-tran'sformed leukemic myeloblasts. Immunoprecipitates from lysates of subcellular fractions of [35S]methionine-labeled BM2 cells (19, 20) were analyzed by gel electrophoresis (Fig. 1A) . p48aamv was specifically detected by anti-peptide antibody only in the nuclear fraction. Parallel analysis of fixed BM2 myeloblasts using indirect immunofluorescent staining with anti-peptide antiserum (21) confirmed the nuclear localization of p48myb ( Fig. 2 A and B) . Preincubation of the anti-peptide antiserum with excess peptide completely inhibited both the immunoprecipitation and the nuclear fluorescence, demonstrating the specificity and correlation of these techniques.
To test the generality of the nuclear location of p48myb in AMV-transformed myeloblasts, we examined leukemic cells obtained from the peripheral blood of several leukemic chickens that had been infected with AMV. Gel electrophoresis of immunoprecipitates from subcellular fractions of all these cells showed the presence of p48myb only in the nuclear fraction (Fig. 1B) . Specific indirect immunofluorescent staining also confirmed the nuclear localization of this protein in freshly explanted leukemic myeloblasts (not shown). Thus the nuclear location of p48mYb in BM2 myeloblasts is not an artifact resulting possibly from long-term in vitro culture and the clonal selection of a specific cell type, since it is also found in the nuclei of peripheral blood leukemic myeloblasts, which are polyclonal and result from multiple transformation events (22 tion, whether immunoprecipitated with amv-specific antiserum ( Fig. 3 A and C) or gag-specific antiserum (Fig. 3B) . The cytoplasmic localization of the gag-containing helper virus proteins Pr76 and Prl8O, as previously reported (24) due to the presence of the cross-reacting cytoplasmic 110,000 Mr protein in these cells (see below) ( Fig. 2 Eand F) . Thus, the leukemogenic protein of the AMV-related E26 virus is also located in the cell nucleus. While antisera raised against amv peptides P1 and P2 recognized p135h1-amv-ets (Fig. 3 A and C) , antiserum against amv peptide P4 did not (not shown). This is in agreement with the molecular analysis of the E26 genome, which indicates that the 3' sequences of amv, including P4, are not present in E26 (16, 17) .
Localization of the Candidate Cellular Homolog p11OP v in Hematopoietic Tissues and Cell Lines. The 110,000 Mr protein initially detected in chicken embryonic thymus by anti-amv peptide antisera (3) has also been found in embryonic bursa, spleen, and yolk sac and in adult thymus and bone marrow, all of which express proto-amv mRNA (12, 25 which do not express proto-amv mRNA (unpublished). AEV-transformed erythroblasts, MSB-1 Marek virus-transformed T lymphocytes (26) , and RP-9 avian leukosis virustransformed B lymphocytes (27) all express proto-amv mRNA (12, 28) and also contain this protein. The intracellular location of this molecule in embryonic bursal and thymic lymphocytes was determined by subcellular fractionation followed by immunoprecipitation and by indirect immunofluorescence. Because these cells are extremely fragile, we substituted a low concentration of digitonin for Kyro-EOB to solubilize the plasma membrane. This prevented nuclear contamination of the other subcellular fractions.
The pll0Proto-amv candidate cellular homolog was immunoprecipitated by antisera against amv peptides P1 and P4 only from the soluble cytoplasmic fraction of embryonic bursal and thymic lymphocytes (Fig. 4) . This fraction contained less than 2% of the total acid-precipitable [3H]thymidine-labeled DNA. Localization of nonspecifically precipitated histone proteins (15,000-20,000 Mr) in the nuclear fraction and of presumed actin (43,000 Mr) and myosin (200,000 Mr) in the cytoplasmic fraction confirmed the relative purity of these subcellular fractions. Indirect immunofluorescent staining of both bursal (Fig. 2 C and D) and thymic (not shown) lymphocytes confirmed the cytoplasmic location of p110. In addition, the cell lines MSB-1 and RP-9 were also labeled with [35S]methionine, fractionated, and immunoprecipitated. Again the 110,000 Mr protein was identified only in the soluble cytoplasmic fraction (Fig. 5) .
DISCUSSION
The product of the AMV oncogene, p48myb (3, 4) , has been localized in the nucleus of AMV-transformed leukemic myeloblasts both by subcellular fractionation followed by spe- gene, P135gag-amve-ets (3, 15, 23) , has similarly been localized in the nucleus of E26-transformed leukemic cells. These findings may reflect a major functional similarity in these two viral oncogene products.
P48myb has been found exclusively in the nucleus in a cloned line of AMV-transformed myeloblasts, which do not contain helper virus, and in polyclonal AMV-transformed peripheral blood leukemic myeloblasts, which do contain helper virus. This protein has been predicted to contain a short viral gag NH2 terminus and a short env COOH terminus (3) (4) (5) . However, neither of these virus-specific terminal sequences is likely to determine the nuclear location of p48myb. Many gag-encoded proteins, including several gagoncogene fusion proteins, have been identified in the cytoplasm (Pr76sas, Pr180ag.Pol, and p130gag-fPs) and plasma membrane (pl20gag-abI), as well as in the nucleus (pll09'6-mYc) (24, (29) (30) (31) (32) . Avian retroviral env gene products, in contrast, have been found only in the cytoplasm and plasma membrane fractions of infected cells (24) . Recent studies of model proteins have suggested that transport into the cell nucleus is directed by specific primary structural determinants (33, 34) . Thus, in the case of p48mY and p135gag amveets, these nucleotropic determinants appear likely to reside within sequences transduced from the cell (amv and amve-ets, respectively). Since primary structural determinants appear to direct proteins into the cell nucleus (33, 34) , the normal homolog of the nuclear p48mYb and p135sag-amv -ets would also be expected to be a nuclear protein.
The cytoplasmic location of the p11OProt°-`mv candidate ceilular homolog is thus unexpected, although several hypotheses for its apparent nuclear absence can be proposed: (i) low *-WA* t* wx = processing and tertiary folding of a nuclear form not recognized by our antibodies; (ii) a short half-life in the nucleus; or (iii) exposure in p48myb of nucleotropic determinants that are "cryptic" in the proto-amv product. However, the lack of detection of p110 by several newly prepared anti-amv peptide antisera that do detect p48mYb and p135gag-amv-ets (un- published) clouds the relationship of p110 to these viral proteins. In addition, another candidate cellular homolog of p48myb, a molecule of 75,000 Mr, has been detected by Klempnauer et al. in AEV-transformed erythroblasts by using antiserum raised against a bacterial myb expression vector product (4). However, this 75,000 Mr protein is detected by only 2 of our 11 anti-peptide antisera that immunoprecipitate p48myb (unpublished) . To help clarify this issue we are preparing antisera against purified p48myb and myb expression vector products.
Other retroviral oncogene products have been localized to various cellular compartments by using techniques similar to those above. The myc andfos products are nuclear proteins; the fps,fms, and mos products are cytoplasmic; and the src, ras, erb B, and abl products are located in the plasma membrane (refs. 29-32 and 35-42; T. Curran, personal communication). The nuclear location of p48myb and p135gag-amv"-ts appears to limit the possible cellular substrate(s) for the exclusively leukemogenic action of AMV and E26.
